UCI clinical trial targeting retinitis pigmentosa receives $6.6M grant from California Institute for Regenerative Medicine – Newswise

Newswise — Irvine, CA- April 13, 2020 – Henry J. Klassen, MD, PhD, professor and director of the Stem Cell and Retinal Generation Program at the UCI School of Medicine, Gavin Herbert Eye Institute, and founder of jCyte, Inc., was awarded a $6.6 million dollar grant from the California Institute for Regenerative Medicine (CIRM) for a clinical trial targeting retinitis pigmentosa (RP).

RP is a blinding eye disease that affects approximately 150,000 people in the United States. It is caused when the light-sensing cells located in the back of the eye called photoreceptors are lost due to a localized form of degeneration. There is currently no treatment for the condition, and it leads to gradual vision loss and eventually blindness.

In previous clinical trials, also funded by CIRM, Klassen and his team of researchers used human retinal progenitor cells (hRPCs) to treat the disease in study subjects. Injected into the gel-filled space in the center of the eye, the progenitor cells secrete neurotrophic factors that have been shown to rescue weak or dormant photoreceptors, slowing and potentially reversing the degenerative process.

“CIRM funds and accelerates promising early stage research, through development and to clinical trials,” says Maria T. Millan, MD, president and CEO of CIRM. “Programs, such as this, that are novel stem cell or gene therapy approaches addressing a small number of patients, often have difficulty attracting early investment and funding. CIRM’s role is to de-risk these novel regenerative medicine approaches that are based on rigorous science and